As on 23 Oct 2026
HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan
EquityNAV
₹ 20.66
CAGR (3 Years)
27.94%
AUM (Cr)
₹ 3,501.37
Risk
Very High Risk
About HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan
To provide long-term capital appreciation by investing predominantly in equity and equity related s securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be realized.
Breakdown of this Fund
Debt Others
4.81%
Healthcare
48.96%
Pharmaceuticals
93.86%